{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:27:47Z","timestamp":1789133267904,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.autrev.2019.102424","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:50:55Z","timestamp":1573761055000},"page":"102424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside"],"prefix":"10.1016","volume":"19","author":[{"given":"Benoit","family":"Brilland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Chevailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Subra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2019.102424_bb0005","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102424_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102424_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.08.016","article-title":"ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis","volume":"120","author":"Finkielman","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0025","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03453.x","article-title":"Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA): minor target antigens in ANCA-associated vasculitis","volume":"150","author":"Talor","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2013101043","article-title":"With complements from ANCA mice","volume":"25","author":"Kettritz","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102424_bb0040","first-page":"921","article-title":"Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis","volume":"135","author":"Jennette","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","article-title":"Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis","volume":"29","author":"Xing","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/039463201202500133","article-title":"Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience","volume":"25","author":"Gigante","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.autrev.2019.102424_bb0055","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2019.102424_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0002-9440(10)62952-5","article-title":"Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha","volume":"167","author":"Huugen","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0065","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood.V86.8.3189.3189","article-title":"Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies","volume":"86","author":"Reumaux","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0070","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1681\/ASN.V1061224","article-title":"A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis","volume":"10","author":"Witko-Sarsat","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0075","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1681\/ASN.2006121309","article-title":"Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies","volume":"18","author":"Brachemi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.153.3.1271","article-title":"Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa","volume":"153","author":"Porges","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1681\/ASN.2013111177","article-title":"Phagocyte NADPH oxidase restrains the inflammasome in ANCA-induced GN","volume":"26","author":"Schreiber","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jbspin.2016.05.013","article-title":"NETosis: at the crossroads of rheumatoid arthritis, lupus, and vasculitis","volume":"84","author":"Berthelot","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2019.102424_bb0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0100","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2012-03-416156","article-title":"Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity","volume":"120","author":"Sangaletti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00256","article-title":"Neutrophil extracellular traps in ANCA-associated vasculitis","volume":"7","author":"S\u00f6derberg","year":"2016","journal-title":"Front Immunol"},{"issue":"Suppl. 103","key":"10.1016\/j.autrev.2019.102424_bb0110","first-page":"33","article-title":"Immune stimulatory effects of neutrophil extracellular traps in granulomatosis with polyangiitis","volume":"35","author":"Lange","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0b013e3283331594","article-title":"Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener\u2019s granulomatosis","volume":"22","author":"Witko-Sarsat","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0125","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI117430","article-title":"C5a-induced expression of P-selectin in endothelial cells","volume":"94","author":"Foreman","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2019.102424_bb0130","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4049\/jimmunol.169.4.2102","article-title":"Complement c3a and c5a induce different signal transduction cascades in endothelial cells","volume":"169","author":"Schraufstatter","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S67264","article-title":"Current and emerging treatment options fo ANCA-associated vasculitis: potential role of belimumab and other BAFF\/APRIL targeting agents","author":"Lenert","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.autrev.2019.102424_bb0140","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar3362","article-title":"T-helper cells as new players in ANCA-associated vasculitides","volume":"13","author":"Abdulahad","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102424_bb0150","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2019.102424_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0160","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0165","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"Chen","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2019.102424_bb0170","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.ki.5002103","article-title":"Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice","volume":"71","author":"Huugen","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0175","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0180","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2019.102424_bb0185","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0190","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/ard.2006.064626","article-title":"Rats and mice immunised with chimeric human\/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes","volume":"66","author":"van der Geld","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102424_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0b013e32834d2d52","article-title":"Animal models of antineutrophil cytoplasm antibody-associated vasculitis","volume":"24","author":"Salama","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0200","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2249.1992.tb05834.x","article-title":"Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils","volume":"90","author":"Shingu","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0215","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0171-2985(96)80050-7","article-title":"Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes","volume":"195","author":"Vogt","year":"1996","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2019.102424_bb0220","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.4049\/jimmunol.158.9.4444","article-title":"Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils","volume":"158","author":"Wirthmueller","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.4754","article-title":"Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5: complement and vasculitis","volume":"240","author":"Freeley","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a Receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0235","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.134.5.3325","article-title":"Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg","volume":"134","author":"Marder","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1523-1755.2002.00139.x","article-title":"C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway","volume":"61","author":"Perianayagam","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0245","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0002-9440(10)61133-9","article-title":"Anti-c5a ameliorates coagulation\/fibrinolytic protein changes in a rat model of sepsis","volume":"160","author":"Laudes","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0250","first-page":"1869","article-title":"Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation","volume":"100","author":"Mollnes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0255","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1083\/jcb.100.5.1641","article-title":"The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin","volume":"100","author":"Becker","year":"1985","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2019.102424_bb0260","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/349614a0","article-title":"The chemotactic receptor for human C5a anaphylatoxin","volume":"349","author":"Gerard","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2019.102424_bb0265","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0161-5890(00)00067-5","article-title":"A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells","volume":"37","author":"Ohno","year":"2000","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0270","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.4049\/jimmunol.1103141","article-title":"C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity","volume":"188","author":"Dunkelberger","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0275","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.4049\/jimmunol.1401401","article-title":"Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse","volume":"194","author":"Karsten","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0280","series-title":"Encyclopedia of immunobiology","author":"Collectif","year":"2016"},{"key":"10.1016\/j.autrev.2019.102424_bb0285","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1021\/bi034489v","article-title":"C5L2, a nonsignaling C5A binding protein","volume":"42","author":"Okinaga","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.autrev.2019.102424_bb0290","doi-asserted-by":"crossref","first-page":"39677","DOI":"10.1074\/jbc.C500287200","article-title":"An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2","volume":"280","author":"Gerard","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2019.102424_bb0295","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.molimm.2008.11.001","article-title":"The human complement fragment receptor, C5L2, is a recycling decoy receptor","volume":"46","author":"Scola","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0300","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1074\/jbc.M109.092106","article-title":"The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction","volume":"285","author":"Bamberg","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2019.102424_bb0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature05559","article-title":"C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a","volume":"446","author":"Chen","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2019.102424_bb0310","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1753","article-title":"Functional roles for C5a receptors in sepsis","volume":"14","author":"Rittirsch","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0315","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1681\/ASN.2006070718","article-title":"Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies","volume":"17","author":"Schreiber","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0320","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102424_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038317","article-title":"p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation","volume":"7","author":"Hao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102424_bb0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0335","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/ar3873","article-title":"C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"14","author":"Yuan","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102424_bb0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000357154","article-title":"Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis","volume":"126","author":"Molad","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.autrev.2019.102424_bb0345","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis","volume":"10","author":"Manenti","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158871","article-title":"Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis","volume":"11","author":"Augusto","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102424_bb0355","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004871","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis","volume":"95","author":"Fukui","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.102424_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195680","article-title":"Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Deshayes","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102424_bb0365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5387\/fms.52.103","article-title":"Usefulness of complement split product, Bb, as a clinical marker for disease activity of lupus nephritis","volume":"52","author":"Watanabe","year":"2006","journal-title":"Fukushima J Med Sci"},{"key":"10.1016\/j.autrev.2019.102424_bb0370","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/shk.0b013e3180342439","article-title":"Role of the alternative pathway in the early complement activation following major trauma","volume":"28","author":"Ganter","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.autrev.2019.102424_bb0375","first-page":"225","article-title":"Specificity of EIA immunoassay for complement factor Bb testing","volume":"57","author":"Pavlov","year":"2011","journal-title":"Clin Lab"},{"key":"10.1016\/j.autrev.2019.102424_bb0380","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0385","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.146.1.257","article-title":"Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution","volume":"146","author":"Pangburn","year":"1977","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0390","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.4049\/jimmunol.163.7.3957","article-title":"Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11","volume":"163","author":"Jarva","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0395","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.102424_bb0400","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0656-8","article-title":"Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102424_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex529","article-title":"Myeloperoxidase influences the complement regulatory activity of complement factor H","author":"Chen","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102424_bb0415","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1681\/ASN.2015060612","article-title":"Mayo clinic\/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN","volume":"27","author":"Sethi","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0420","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0425","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archderm.1977.01640020047008","article-title":"Cutaneous manifestations of Wegener granulomatosis","volume":"113","author":"Hu","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-1797.2009.01086.x","article-title":"Review article: pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis","volume":"14","author":"Van Timmeren","year":"2009","journal-title":"Nephrology"},{"key":"10.1016\/j.autrev.2019.102424_bb0435","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1111\/j.1523-1755.2004.00632.x","article-title":"Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases","volume":"65","author":"Haas","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0440","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ndt\/gfv288","article-title":"Complement in ANCA-associated glomerulonephritis","volume":"32","author":"Hilhorst","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.102424_bb0445","first-page":"179","article-title":"Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis","volume":"142","author":"Schulze","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2019.102424_bb0450","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ndt\/gfn586","article-title":"Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis","volume":"24","author":"Chen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.102424_bb0455","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10875-009-9344-2","article-title":"Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis","volume":"30","author":"Xing","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0460","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1681\/ASN.2014040406","article-title":"C4d as a diagnostic tool in proliferative GN","volume":"26","author":"Sethi","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0465","doi-asserted-by":"crossref","first-page":"i139","DOI":"10.1093\/ndt\/gfw299","article-title":"Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.102424_bb0470","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.ajkd.2012.03.007","article-title":"Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis","volume":"60","author":"Fervenza","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2019.102424_bb0475","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4049\/jimmunol.135.3.2063","article-title":"Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN)","volume":"135","author":"Huey","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0480","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1074\/jbc.C100714200","article-title":"The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg 74","volume":"277","author":"Cain","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2019.102424_bb0485","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cei.13051","article-title":"Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: complement regulatory proteins in AAV","volume":"191","author":"Cheng","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2019.102424_bb0490","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2010.472","article-title":"New pathophysiological insights and treatment of ANCA-associated vasculitis","volume":"79","author":"Wilde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.102424_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102424_bb0500","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2019.102424_bb0505","first-page":"2016","article-title":"A Randomized clinical trial of CCX168, an orally administered C5aR inhibitor for treatment of patients with ANCA-associated vasculitis (abstract)","volume":"68","author":"Merkel","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0510","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2019.102424_bb0515","series-title":"Biostatistics for biomedical research","author":"Harrell","year":"2016"},{"key":"10.1016\/j.autrev.2019.102424_bb0520","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-264","article-title":"Comparisons against baseline within randomised groups are often used and can be highly misleading","volume":"12","author":"Bland","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2019.102424_bb0525","series-title":"Phase 3 clinical trial of CCX168 (avacopan) in patients with ANCA-associated vasculitis (ADVOCATE) (NCT02994927)","author":"ChemoCentryx","year":"2016"},{"issue":"Suppl. 103","key":"10.1016\/j.autrev.2019.102424_bb0530","first-page":"199","article-title":"Maintenance treatment of ANCA-associated vasculitides","volume":"35","author":"Guillevin","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0535","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40674-017-0082-y","article-title":"Avoidance of harm from treatment for ANCA-associated vasculitis","volume":"3","author":"King","year":"2017","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.autrev.2019.102424_bb0540","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102424_bb0545","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.102424_bb0550","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key288","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody\u2013associated vasculitis","author":"Pepper","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2019.102424_bb0555","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy075","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","author":"McAdoo","year":"2018","journal-title":"Nephrol Dial Transplant"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:19Z","timestamp":1761599779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1568997219302344"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102424","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102424"}}